TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aquamin F on Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Subjects aged 35 to 75, male or female~* Subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the American College of Rheumatology17, 18~* Subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician.~* Subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis.~* Subjects with screening WOMAC Osteoarthritis Index total score (transformed score) of not more than 75.~* Subjects with ability to comprehend and complete the questionnaires and forms.~* Subjects whose schedules permit clinic evaluations every four weeks.~* Subjects who are willing to stop taking calcium supplements, if any, and to restrict consumption of high calcium foods to 600 mg (two dairy serving) per day~* Subjects with a high probability of compliance with study procedures and test article consumption.~* Subjects willing and able to follow protocol guidelines and schedules, and complete diaries.~* Subjects who are likely to abstain from taking unauthorized supplements or participating in any other clinical trial or experimental treatment during this trial~* Subjects with normal gastrointestinal digestion and absorption.~Exclusion Criteria~* Subjects suffering from inflammatory arthritis, gout, pseudogout, Paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or HIV infection.~* Subjects who are non-ambulatory or bedridden due to osteoarthritis.~* Subjects who are dependent on prescription drugs to control pain.~* Subjects on any other clinical trial or experimental treatment in the past 3 months~* Subjects who are pregnant, lactating, or at risk of becoming pregnant.~* Subjects who have received:~  * Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) within 48 hours prior to study enrollment.~ * Intramuscular or systemic corticosteroid injection within 4 weeks prior to study enrollment.~ * Intra-articular corticosteroid injection within 2 months prior to study enrollment.~ * Intra-articular hyaluronic acid injection within 4 months prior to study enrollment.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Characteristics of Glargine in Type 2 Diabetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 12 adults (males or females) with type 2 diabetes for at least six (6) months. May be using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin.~* HgbA1c 7 -12%~* Age 18-70 years~* BMI 27-40 kg/m²~Exclusion Criteria:~* Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study~* Evidence of hepatic, renal or cardiac failure~* Abnormal results following screening tests~* Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception~* Currently using TZDs~* History of alcoholism or drug abuse within 12 months of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo then Insulin Glargine (Type: EXPERIMENTAL): Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet the following criteria to be eligible for the study:~1. Histologically confirmed colorectal cancer or breast cancer, of which colorecta cancer is advanced or undergoing adjuvant therapy after radical resection and breast cancer is at the stage of recurrence or metastasis;~2. Level 1 or above HFS after receiving capecitabine as part of routine standard care;~3. Plan to receive capecitabine as part of routine more than 2 weeks;~4. ECOG performance status 0-2;~5. Life expectancy greater than or equal to 3 months;~6. No serious heart, liver, kidney and other important viscera dysfunction, as defined below:~   * absolute neutrophil count greater than or equal to 1.5 x 10(9)/L~  * platelet count greater than or equal to 100 x 10(9)/L~  * hemoglobin greater than or equal to 9.0 g/dL~  * total bilirubin less than or equal to 1.5 times the ULN~  * AST/SGOT and ALT/SGPT less than or equal to 2.5 times the ULN (or less than or equal to 5 times the ULN if liver function abnormalities due to underlying malignancy)~  * creatinine less than or equal to 1.5 times the ULN~  * creatinine clearance greater than or equal to 60 ml/min (by Cockcroft-Gault)~7. Ability to cooperate with HFS grade evaluation, understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~Subjects meeting any of the following criteria are ineligible for study entry:~1. Concurrent with level 1 or above peripheral neuropathy (such as diabetic neuropathy or chemotherapy induced peripheral neuropathy);~2. Other acute or chronic inflammatory conditions or infections of the hands or feet that would complicate safety, application of topical creams, or study endpoints;~3. Currently taking other treatment for PPE (including topical urea cream, pyridoxine, celecoxib, compound matrine injection and deproteinized calf blood extractive injection);~4. History of severe or uncontrolled organic disease or infection, such as heart, pulmonary or renal failure that cause the termination of chemotherapy;~5. Pregnant (positive pregnancy test) or nursing women;~6. Participating in other clinical trial currently or within 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive placebo by soaking their affected hand and feet 20 min twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Safety Study in Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with 2-8 moderate to severe migraines/month~* Age of onset of migraines prior to 50 years of age~* Migraine attacks, on average, lasting 4-72 hours if untreated~* Ability to distinguish migraine attacks from tension/cluster headaches~* Patients with contraindications for use of triptans may be included provided they meet all other study entry criteria~Key Exclusion Criteria:~* History of basilar migraine or hemiplegic migraine~* History of HIV disease~* History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia.~* Uncontrolled hypertension or uncontrolled diabetes (however, patients can be included who have stable hypertension and /or diabetes for 3 months prior to screening~* History of gastric or small intestinal surgery or has a disease that causes malabsorption~* BMI ≥ 30~* HbA1c ≥ 6.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rimegepant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Ventricular Remodeling With Toprol-XL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of stable asymptomatic heart failure.~* Documented ejection fraction less than 0.40.~* Must be able to comply with all study procedures.~Exclusion Criteria:~* Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.~* Have heart problems that would not allow B-blocker therapy.~* Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).~* Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.~* Have certain heart diseases.~* Pregnant or breast feeding.~* Unlikely to survive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naive males and females, \>= 18 years old and~\<= 77 years old, with type 2 diabetes mellitus~* Subjects must have central laboratory pre-randomization hemoglobin A1C \>= 7.5 and \<= 12.0%~* C-peptide \>= 1.0 ng/mL (0.34 nmol/L)~* Body Mass Index \<= 45 kg/m2~* Must be able to perform self monitoring of blood glucose~Exclusion Criteria:~* aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>3X\*upper limit of normal (ULN)~* Serum Total bilirubin \>2 mg/dL (34.2 µmol/L)~* Creatinine kinase \>3\*ULN~* Serum creatinine \>= 1.50 mg/dL (133 µmol/L) for male subjects, \>= 1.40 mg/dL (124 µmol/L) for female subjects~* Calcium value outside of the central laboratory normal reference range~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases~* Urine albumin:creatinine ratio (UACR) \>1800 mg/g (203.4 mg/mmol Cr)~* Severe uncontrolled hypertension defined as systolic blood pressure (SBP) \>=180 mmHg and/or diastolic blood pressure (DBP) \>=110 mmHg~* Hemoglobin \>=11.0 g/dL (110 g/L) for men; hemoglobin \>=10.0 g/dL (100 g/L) for women~* Positive for hepatitis B surface antigen~* Positive for anti-hepatitis C virus antibody~* History of diabetes insipidus~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* Symptoms of poorly controlled diabetes that would preclude participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin + Metformin XR (Type: EXPERIMENTAL): Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks
- Dapagliflozin + Placebo (Type: EXPERIMENTAL): Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.
- Metformin XR + Placebo (Type: ACTIVE_COMPARATOR): Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Within a 90-day period prior to the patient recruitment date:~* ≥30 days of prescriptions for opioid medications; or~* 2 or more opioid prescriptions; or~* a total amount of ≥700 Morphine Milligram Equivalents (MME) in a single opioid prescription;~and~* Patients who have had 1 or more Cedars-Sinai Medical Group primary care physician in the year prior to the study start date; and~* At least 1 visit during the follow-up year (the follow-up year will start after they consent to be in the study).~Prescriptions in the inpatient setting will not make a patient eligible for this study.~Exclusion Criteria:~* Individuals less than 18 years of age; or~* Individuals with any cancer treatment (chemotherapy or radiotherapy) administered 180 days or less prior to patient recruitment; or~* Individuals with a cancer diagnosis in the Problem List 180 days or less prior to patient recruitment (patients with cancer surveillance only will be included in the study); or~* Individuals with palliative care treatment administered 180 days or less prior to patient recruitment; or~* Individuals with any end-of-life treatment (comfort care) prior to patient recruitment; or~* Patients currently taking prescription medications (e.g. Suboxone, subutex, Buprenex, Butrans, Probuphine, Belbuca, buprenorphine/naloxone, Zubsolv, and Bunavail) for Opioid Use or other Substance Use Disorder treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clinical Decision Support (Type: EXPERIMENTAL): Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
- Patient Education and Activation Tools (Type: EXPERIMENTAL): Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singleton Pregnancy~* Indicated for IUPC~* Gestational ages from 37 to 41 weeks~* Informed consent required~Exclusion Criteria:~* Multifetal pregnancy~* Not Indicated for IUPC~* Gestation age below 37 or above 41 weeks~* Informed consent not given

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Pregnant, In Labor (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children with a diagnosis of chronic lung disease (CLD) secondary to bronchopulmonary dysplasia (BPD) as defined by ATS.~* children who receive primary care at High Risk Infant Clinic or High Risk Children's Clinic~Exclusion Criteria:~* Children with Cystic Fibrosis or bronchiectasis~* Children with cardiac arrhythmias~* Children with cyanotic heart disease~* Children with colitis~* Children with a known Macrolide allergy~* Children taking medications known to interact with macrolides~* Children with short bowel syndrome~* Children with kidney or liver failure

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
- azithromycin (Type: EXPERIMENTAL): Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre Operative Transversus Abdominis Plane Block Laparoscopic Gynecological Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-64 years~* Surgery: Outpatient Gynecological laparoscopic surgery~* ASA status: I and II~* Fluent in English~Exclusion Criteria:~* History of allergy to local anesthetics~* History of chronic opioid use~* Pregnant patients~* BMI greater than 30~Drop-out criteria:~* Patient or surgeon request~* Complications related to the procedure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine 0.05% (Type: ACTIVE_COMPARATOR): Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
- Normal Saline (Type: PLACEBO_COMPARATOR): Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
- Ropivacaine 0.25% (Type: ACTIVE_COMPARATOR): Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Are at least 18 years of age.~2. Have a diagnosis of primary SS according to the updated American European Consensus Group Criteria -~Exclusion Criteria:~1. Have received treatment with any BLyS-targeted (BLyS-receptor fusion protein \[BR3\], TACI Fc, or belimumab) at any time.~2. Have a Grade 3 or greater laboratory abnormality based on the protocol toxicity scale except for the following that are allowed:~   * Stable Grade 3 prothrombin time (PT) secondary to warfarin treatment.~  * Stable Grade 3/4 proteinuria (≤ 6 g/24 hour equivalent by spot urine protein to creatinine ratio allowed).~  * Stable Grade 3 neutropenia or stable Grade 3 white blood cell count

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-64 years (both inclusive) at the time of signing informed consent~* Body mass index 18.5-28.0 kg/m\^2 (both inclusive)~* Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator~Exclusion Criteria:~* Known or suspected hypersensitivity to trial products or related products~* Previous participation in this trial. Participation is defined as informed consent~* Presence of clinically significant acute and chronic gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to first dosing, as judged by the investigator

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Eating meal immediately after dosing (Type: EXPERIMENTAL): None
- Eating meal 30 min after dosing (Type: EXPERIMENTAL): None
- Eating meal 1 hour after dosing (Type: EXPERIMENTAL): None
- Eating meal 6 hour after dosing (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 years of age or older at time of enrollment~* may be male or female~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to screening~* Have plaque-type psoriasis covering at least 10% of total BSA at baseline~* Have previously received PUVA and/or other systemic treatment for psoriasis~Exclusion Criteria:~* Have non-plaque forms of psoriasis~* Have a history of drug-induced psoriasis~* Are pregnant, nursing, or planning pregnancy within 12 months of enrollment~* Have had any previous treatment with infliximab or any therapeutic agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete